Call Now

(214) 444-9555

GeneAlign Company News | Industry News

  • Home
  • GeneAlign Company News | Industry News

GeneAlign Company News

Pacira Partnership

GeneAlign and Pacira Pharmaceuticals have come together to develop an innovative solution to the growing problem of opioid addiction. Multiple studies have indicated that as many as one in ten surgical patients become dependent on the opioids prescribed following the procedure. Read about our efforts to combat this serious problem here:

GeneAlign Industry News

Companies Collaborate To Reduce Postsurgical Opioid Dependence

A new initiative to identify preoperative patients who may be predisposed to developing dependence on opioid analgesics could facilitate treatment plans that reduce their exposure to opioids and mitigate that risk. The joint endeavor by specialty pharmaceutical manufacturer Pacira Pharmaceuticals and therapeutic management firm GeneAlign has incorporated behavioral histories and pharmacogenetic and pharmacogenomic testing into the preoperative risk assessments for selected procedures at pilot institutions.

Cigna Anti-Opioid Pledge

Cigna is asking medical providers to sign a pledge to reduce the prescription of opioids. As part of the effort, physicians are encouraged to “screen patients for opioid use disorder” and to “reduce opioid prescriptions by prescribing alternative therapies when they are available”.

Opioid use overtakes tobacco

The federal Substance Abuse and Mental Health Services Administration recently released a survey that found 37.8% of US adults use prescription painkillers, while 31% use tobacco. In Tennessee, more people died from an opioid overdose in 2014 than died in car crashes or from gun violence.

Louisiana Opioid Taskforce

Louisiana has created the Commission on Preventing Opioid Abuse to develop recommendations to curb the use of prescription opioids and heroin in the state. Louisiana ranks seventh in the country in the rate of opioid prescriptions.